BMY$49.08
$49.3
Chart
Performance
Key Stats
AI BMY Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBristol-Myers Squibb exhibits strong fundamental characteristics with a consistent dividend and a diversified product portfolio in key therapeutic areas. While recent performance has been mixed and some technical indicators suggest short-term caution, its long-term prospects are supported by its established market position and ongoing R&D efforts.
Thematic
Bristol-Myers Squibb operates in the biopharmaceutical sector, which benefits from global healthcare spending trends and innovation in treatment areas like oncology and immunology. However, the sector is highly competitive and subject to regulatory scrutiny and patent expirations.
Fundamental
Bristol-Myers Squibb demonstrates solid financial health with consistent revenue generation, strong profitability, and a manageable debt level. Its dividend yield is attractive, and the company generates substantial free cash flow, supporting its operations and shareholder returns.
Technical
The stock is trading below its 52-week high and shows mixed signals across different timeframes. While some moving averages indicate potential support, recent performance and certain oscillator readings suggest a cautious outlook in the short to medium term.
| Factor | Score |
|---|---|
| Oncology Market Growth | 80 |
| Immunology & Inflammation Trends | 75 |
| Drug Pipeline & Innovation | 70 |
| Regulatory Landscape | 50 |
| Patent Expirations | 40 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 70 |
| Growth | 60 |
| Balance Sheet Health | 55 |
| Cash Flow | 85 |
| Dividend Yield | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 60 |
| Price Performance (6M) | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
Bristol-Myers Squibb (BMY) has consistently beaten EPS estimates in recent quarters, with surprises of 20.55%, 14.67%, and 20.71% in its latest three reported quarters, indicating strong operational execution and efficient cost management.
Reasonable P/E Ratio
The trailing Price-to-Earnings (P/E) ratio of 18.26 is competitive within the pharmaceutical industry and suggests the stock is not excessively overvalued given its earnings.
Bearish Points (7)
Slowing Revenue Growth (Annual)
Annual revenue growth has decelerated from 2021 ($46.385B) to 2024 ($48.300B), with a notable dip in net income in 2024 (-$8.948B), indicating potential headwinds or challenges in top-line expansion and profitability.
Negative Net Margin in Latest Quarter
The company reported a significantly negative net margin of -100.4% in Q1 2024, driven by a large net loss, which raises concerns about the sustainability of current operations and profitability.
Calendar
July 2025
3
Ex-Dividend Date
July 2025
31
Next Earnings Date
H: $1.67
A: $1.13
L: $0.96
H: 11.77B
A: 11.39B
L: 11.19B
August 2025
1
Next Dividend Date
Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Seasonals
Price Target
56.55 USD
The 39 analysts offering 1 year price forecasts for BMY have a max estimate of 68.00 and a min estimate of 34.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct Competitor: A global pharmaceutical giant with overlapping therapeutic areas including oncology, immunology, and cardiovascular diseases, actively developing and marketing similar drug classes.
Weight: 90
Direct Competitor: Major pharmaceutical company with a strong presence in oncology (Keytruda), vaccines, and hospital acute care, competing for market share and R&D talent.
Weight: 88
Direct Competitor: A diversified healthcare company with a significant pharmaceutical segment that directly competes with BMY in areas like oncology, immunology, and neuroscience.
Weight: 87
Direct Competitor: A leading biopharmaceutical company specializing in immunology (Humira), oncology, and neuroscience, often competing for the same patient populations and drug development pipelines.